What CVPath Institute does

CVPath Institute is a 501(c)(3) non-profit cardiovascular pathology research organization founded in 2005 by Dr. Renu Virmani and headquartered in Gaithersburg, Maryland, along the I-270 Technology Corridor. The institute provides expert translational bench-to-bedside research services to medical technology companies globally, ranging from startups to Fortune 100 manufacturers. Its portfolio covers histology, CAP-accredited and CLIA-approved diagnostic pathology for autopsy and surgical specimens, GLP-compliant preclinical device trials, medical device evaluation across the full cardiovascular anatomy, advanced imaging (including a custom Nikon XT H 225ST Micro-CT, OCT, IVUS, and NIR spectroscopy), and a molecular biology laboratory. The institute is also an educational organization, running a competitive 1-4 year fellowship program, summer internships, and the 'Hands on Hearts' cadaveric workshop delivered at major cardiovascular conferences (CRT, TCT).

Name

CVPath Institute

Legal name

CVPath Institute Inc.

Website

https://cvpath.org

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

CVPath Institute is a 501(c)(3) non-profit cardiovascular pathology research organization providing histology, CAP/CLIA diagnostic, GLP preclinical, and consultation services to medical device companies globally, anchored by a 7,000+ autopsy-heart biobank.

Ownership category

akta.pro rank

Product category

Cardiovascular Pathology Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Educational Services (8200), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG)

akta.pro secondary industries

General Cardiology (Consultative) (HLAKABAA), Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ), Clinical Research Support (CRC/CTA) (EDAOAJAO)

Keywords

• Cardiovascular pathology research
• Preclinical medical device testing
• Cardiovascular tissue biobank
• GLP-compliant histology services
• Diagnostic cardiovascular laboratory

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Consultation Services: Expert translational bench-to-bedside research services including guidance on device safety, mechanism of action studies, and FDA responses. Provided globally to companies from startups to Fortune 100 manufacturers.
2. Histology Services: Comprehensive histology services including grossing, tissue processing (dehydration, clearing, infiltration), paraffin and plastic embedding and sectioning, H&E staining, frozen sectioning, and special stains for amyloids, bacteria, chemicals, and minerals.
3. Diagnostic Laboratory Services: CAP-accredited and CLIA-approved diagnostic services for autopsy and surgical human specimens. Analysis includes heart tissue evaluation, endomyocardial biopsies, pericardial biopsy/resection, vascular specimens, cardiac device examination, and congenital heart disease devices.
4. Preclinical Trials and Device Testing: Study design consultation and small-scale device testing in vascular restenosis models from feasibility through GLP compliant regulatory submission. In-house preclinical models include small animals (rabbits and swine) with acute and chronic study capabilities. Services include biocompatibility, safety, and pharmacokinetic testing.
5. Imaging Services: Ex-vivo and in-vivo intravascular imaging tools including OCT, IVUS, angioscopy, near-infrared spectroscopy, and Micro-CT analysis. Coregistration services between histology and imaging modalities. State-of-the-art OCT core laboratory analysis.
6. Governmental, Philanthropic, and Private Sector Research Grants: The institute is supported by governmental, philanthropic, and private sector funding to conduct independent cardiovascular research. Examples include $10M GCRFF network grant for SHE-HEALS study and ARPA-H grant for smart stent research with Triton Systems.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

CVPath Institute is a non-profit 501(c)(3) research organization that provides expert translational bench-to-bedside cardiovascular pathology services to medical device companies and academic researchers. Its offerings span histology, CAP-accredited/CLIA-approved diagnostic pathology, GLP-compliant preclinical device testing, advanced imaging (OCT, Micro-CT, IVUS, NIR spectroscopy), molecular biology, and a 7,000+ heart tissue biobank, complemented by fellowship and educational programs.

Product overview

CVPath Institute is a non-profit medical research and educational organization (501(c)(3)) dedicated to cardiovascular pathology research and services. The organization offers a comprehensive suite of consultation and laboratory services rather than a unified software product. Core services include histology, diagnostic (CAP-accredited/CLIA-approved), preclinical trials, medical device evaluation, clinical specimen services, and advanced imaging (OCT, Micro-CT). Supporting capabilities include a Heart Lab, Molecular Biology Laboratory, Tissue Biobank (7,000+ autopsy hearts), Genomic Research Services, and Registry Studies. Educational offerings comprise the Hands on Hearts Workshop, Fellowship Program (1-4 years), and Summer Internship Program. Services are provided globally to medical device companies from startups to Fortune 100, supporting device safety evaluation, FDA responses, and regulatory submissions.

Differentiator

Problem solved

Functional benefit

Products and services

• Consultation Services Expert translational bench-to-bedside research services for medical device companies, including guidance on device safety, mechanism of action studies, FDA responses, and regulatory consultation for 510K and IDE approvals.
• Histology Services Comprehensive histology services including grossing, tissue processing, paraffin and plastic embedding and sectioning, H&E staining, frozen sectioning, and special stains for identifying amyloids, bacteria, chemicals, and minerals in diseased tissue.
• Diagnostic Services CAP-accredited and CLIA-approved diagnostic services for autopsy and surgical human specimens including heart tissue evaluation, endomyocardial biopsies, vascular specimens, cardiac devices (stents, valves, pacemakers), and congenital heart disease devices.
• Preclinical Trials Study design consultation and small-scale device testing in vascular restenosis models from feasibility through GLP-compliant regulatory submission, including biocompatibility, safety, and pharmacokinetic testing using rabbit and swine coronary and peripheral models.
• Medical Device Evaluation Expert pathology evaluation of medical devices across the entire anatomical cardiovascular territory including cerebral, carotid, aorta, heart valves, coronary arteries, renal, and peripheral devices with expertise in stent-grafts, TAVI, prosthetic valves, and drug-coated balloons.
• Clinical Specimen Services Full array of diagnostic services for autopsy and surgical specimens including cardiovascular toxicity assessment, medical device evaluation, whole heart grossing, excised atherosclerotic plaque analysis, and thrombectomy material examination.
• Imaging Services Comprehensive microscopy technologies including Optical Coherence Tomography (OCT), Micro-CT imaging using a Nikon XT H 225ST scanner for nondestructive 3D imaging, intravascular ultrasound, angioscopy, and near-infrared spectroscopy with coregistration services between histology and imaging modalities.
• Tissue Biobank

Quantifiable outcome

• Over 7,000 autopsy hearts archived and analyzed for cardiovascular pathology research
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• Global Cardiovascular Research Funders' Forum (GCRFF) / SHE-HEALS ConsortiumcoreStrategic or Co-development PartnerCVPath is a participant in the SHE-HEALS study (Sex-specific Health Effects of Estrogen, Lipids, and Menopause: The Early After Menopause study), a $10 million network grant awarded by GCRFF through the International Research Challenge on Women's Cardiovascular Health. The consortium spans 13 institutions across 7 countries and is led by BHF Professor Ziad Mallat (University of Cambridge) and Professor Martha Hickey (University of Melbourne). CVPath contributes cardiovascular pathology expertise to investigate how menopause shapes heart health.
• Triton SystemscoreStrategic or Co-development PartnerTogether with Triton Systems, CVPath was awarded a grant from the Advanced Research Projects Agency for Health (ARPA-H) to study 'Continuous Monitoring of Cardiovascular Health Using Smart Stents' (ARPA-H-03). The project evaluates the use of a novel 'smart stent' capable of providing real-time information about hemodynamics and troponin-sensing.
• Office of the Chief Medical Examiner of the State of MarylandcoreOthersCVPath has collected over 7,000 autopsy hearts from the Office of the Chief Medical Examiner of the State of Maryland and other contributors since the 1990s. This partnership forms the foundation of the institute's biorepository and sudden death registry.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• NAMSA: NAMSA is the largest specialty medical device CRO, offering GLP preclinical testing, biocompatibility, regulatory consulting, and pathology support. It is the most direct comparable to CVPath's preclinical, GLP, and regulatory submission services for medical device manufacturers.
• Baim Institute for Clinical Research: Baim Institute (formerly Harvard Clinical Research Institute) is a cardiovascular-focused clinical research organization offering clinical trial design, regulatory support, and outcomes research to medical device and pharmaceutical sponsors. Comparable to CVPath as a cardiovascular-specialized research partner for device manufacturers.
• Cardiovascular Research Foundation (CRF): CRF runs the TCT conferences and runs clinical research and education programs in interventional cardiology. Like CVPath, it serves as a translational hub connecting cardiovascular device manufacturers, physicians, and researchers, with overlapping scientific leadership communities.

Broad incumbents

• Duke Clinical Research Institute (DCRI): DCRI is one of the largest academic clinical research organizations globally, with deep cardiovascular clinical trial expertise for pharmaceutical and device sponsors. Comparable to CVPath as a cardiovascular CRO with research authority, though broader in scope and anchored to Duke rather than pathology-focused.
• Charles River Laboratories: Charles River is a global CRO with extensive preclinical, GLP, and safety testing services across medical device and pharma. It competes with CVPath for medical device preclinical work but operates at vastly greater scale and across many therapeutic areas.
• Eurofins Medical Device Testing: Eurofins runs a global network of medical device testing labs including biocompatibility, GLP preclinical, and material characterization. Comparable to CVPath as a service provider for medical device safety and regulatory submissions, though far broader and less specialty-cardiovascular focused.
• Medpace: Medpace is a mid-sized CRO with significant cardiovascular clinical trial experience. Comparable to CVPath as a CRO partner for cardiovascular sponsors, though at clinical-stage scale rather than preclinical/GLP pathology.
• ICON plc: ICON is a top-5 global CRO offering preclinical, clinical, and regulatory services with cardiovascular subspecialty expertise. Comparable in being a one-stop partner for medical device regulatory pathways, though CVPath's cardiology pathology depth is uniquely specialized.
• ARUP Laboratories: ARUP is a large academic reference laboratory offering specialty pathology and clinical diagnostics. Comparable to CVPath's CAP/CLIA-accredited diagnostic laboratory practice, though ARUP covers broad anatomic and clinical pathology rather than cardiovascular-focused.

Emerging players

• Pacific BioLabs (now part of Eurofins): Pacific BioLabs was a specialty medical device preclinical testing CRO before its Eurofins acquisition, offering GLP services similar to CVPath's preclinical offerings to Bay Area device manufacturers. Comparable as a smaller, specialty device-testing CRO with overlapping service lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CVPath_Md
• LinkedInlinkedin.com/company/cvpath-institute-inc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CVPath Institute